Karcinoza možganskih ovojnic in rak dojk
Leptomeningeal carcinomatosis and breast cancer
11-year treatment outcomes with radiation therapy
Keywords:
breast cancer, leptomeningeal carcinomatosis, radiation therapy, prognostic indexAbstract
Uvod: Karcinoza mening (LMK) nastane z zasevanjem tumorskih celic na možganske ovojnice in pomeni slabo prognozo. Obsevanje je ena izmed možnosti zdravljenja za ublažitev nevroloških simptomov.
Metode: V retrospektivno analizo smo vključili 423 bolnic z rakom dojk (RD) in možganskimi zasevki (MZ) ali LMK, ki so se v obdobju med 2005 in 2015 z obsevanjem glave zdravile na Onkološkem inštitutu Ljubljana. Podrobneje smo analizirali skupino bolnic z LMK, za katere smo tudi preverili uporabnost prognostičnih indeksov preživetja Breast Graded Prognostic Assessment (Breast-GPA) in Simple Survival Score for Brain Metastases (SS-BM).
Rezultati: Z obsevanjem glave smo v analiziranem obdobju zdravili 70 bolnic z LMK. Srednji čas od diagnoze RD do pojava LMK je znašal 4,3 leta, vendar je bil ta čas najkrajši pri trojno negativnem in najdaljši pri luminal A podtipu RD. Srednje celokupno preživetje je za bolnice z MZ in LMK znašalo 7,5 (95 % interval zaupanja, IZ; 6,3–8,8) ter 2,3 meseca (95 % IZ; 1,5–3,2) (p < 0,005), in se je razlikovalo tudi glede na molekularni podtip RD. Na daljše preživetje ni vplivala višja prejeta doza obsevanja (≤ 20Gy vs. > 20Gy), kakor tudi ne hiter pričetek obsevanja znotraj prvih dveh tednov po postavitvi diagnoze LMK. Indeksa Breast-GPA (p < 0,005) in SS-BM (p = 0,044) sta statistično značilno napovedala razlike v preživetju.
Zaključki: Pričakovano preživetje se je v naši skupini analiziranih bolnic z LMK razlikovalo glede na stanje zmogljivosti, molekularni podtip RD, čas od diagnoze LMK do pričetka z obsevanjem ter točke prognostičnih lestvic.
Abstract (Eng)
Introduction: Leptomeningeal carcinomatosis (LMC) develops with infiltration of leptomeninges by malignant cells and means poor prognosis. Radiotherapy presents one of the treatment options for neurological symptom relief.
Methods: We retrospectively analyzed 423 patients with breast cancer (BC) and brain metastasis (BM) or LMC, who received radiotherapy of the brain between the years 2005–2015 at the Institute of Oncology Ljubljana. We analyzed patients with LMC in more detail and performed a validation of prognostic survival indexes, namely Breast Graded Prognostic Assessment (Breast-GPA) and Simple Survival Score for Brain Metastases (SS-BM).
Results: Seventy patients with LMC were treated with whole-brain radiotherapy in observed time. Median time from BC diagnosis to LMC appearance was 4,3 years and was shortest in triple-negative and longest in luminal A BC subtype. Median overall survival for patients with BM and LMC was 7,5 (95 % confidence interval, CI; 6,3–8,8) and 2,3 months (95 % CI; 1,5–3,2), respectively (p < 0,005), and it varied depending on molecular BC subtype. Survival was not affected by a higher total dose of radiation received (≤ 20 Gy vs. > 20 Gy) or by the immediate start of radiotherapy within two weeks from LMC diagnosis. Breast-GPA (p < 0,005) and SS-BM (p = 0,044) indexes predicted survival with statistical significance.
Conclusions: Performance status, BC molecular subtype, time from LMC diagnosis till the start of radiotherapy and prognostic indexes were all factors which influenced expected survival in our group of analyzed LMC patients.
Downloads
Published
How to Cite
Issue
Section
License
The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.
This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.